SLU-PP-332

Quick Facts

Introduction

SLU-PP-332 is a synthetic small molecule developed in academic medicinal-chemistry research as an agonist of the estrogen-related receptors (ERRs) — a family of orphan nuclear receptors that sit at the center of how cells program their oxidative metabolism. It has attracted attention in preclinical work as a candidate exercise-mimetic: a compound studied for its association with the same transcriptional changes that endurance training produces in skeletal muscle. Within the broader landscape of metabolic research tools it is frequently grouped with other non-hormonal metabolic agents such as the NNMT inhibitor 5-Amino-1MQ and the mitochondrial uncoupler BAM-15.

Unlike peptide secretagogues or incretin analogues, SLU-PP-332 works inside the cell at the level of gene transcription. The ERRs partner with the coactivator PGC-1α — the master regulator of mitochondrial biogenesis — and SLU-PP-332 is studied as a way to switch that partnership on pharmacologically rather than through the physiological stimulus of exercise. This conceptual framing is what makes it interesting alongside mitochondrial-derived peptides such as MOTS-c, which converge on overlapping bioenergetic endpoints from a different molecular angle.

This profile covers what SLU-PP-332 is, its molecular characteristics as a non-peptide ERR agonist, the PGC-1α/ERR mechanism it engages, the metabolic and exercise-mimetic research it appears in, and how it compares with related metabolic compounds. Related entries are catalogued in the peptide database.

What is SLU-PP-332?

SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptor family, emerging from nuclear-receptor pharmacology research associated with the Burris laboratory. Despite the 'estrogen-related' name, the ERRs do not bind estrogen and are not part of classical estrogen signaling; they are constitutively active orphan receptors named for their sequence homology to the estrogen receptors. SLU-PP-332 is studied as a tool to increase their activity above baseline.

The compound is a non-peptide, meaning it has no amino-acid sequence and is handled in the laboratory more like a classical drug-discovery scaffold than like a reconstituted peptide. Its research interest derives almost entirely from the downstream transcriptional program it engages rather than from any direct enzymatic or hormonal activity of its own.

Molecular and structural characteristics

SLU-PP-332 is a lipophilic small molecule designed to occupy the ligand-binding pocket of the ERRs and stabilize an active receptor conformation. Because the ERRs are constitutively active even without a ligand, SLU-PP-332 functions as an agonist that further increases their transcriptional output rather than switching a silent receptor on from zero. Among the ERR isoforms it is described as a pan-agonist with notable activity at ERRα, the isoform most strongly implicated in muscle and adipose metabolism.

Because it is not a peptide, SLU-PP-332 does not require the aqueous reconstitution workflow used for compounds like MOTS-c; in vitro studies typically dissolve it in an organic co-solvent. This is one of the practical features that distinguishes it from the injectable peptides catalogued in the peptide database.

Mechanism of action

SLU-PP-332 binds the ligand-binding domain of the estrogen-related receptors and amplifies their constitutive transcriptional activity. The ERRs work in concert with PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the coactivator that orchestrates the synthesis of new mitochondria. By increasing ERR activity, SLU-PP-332 is studied as a way to push this PGC-1α/ERR axis toward a more oxidative, energy-burning transcriptional state.

The genes downstream of the ERRs include large swathes of the machinery for oxidative phosphorylation, fatty-acid oxidation, the tricarboxylic-acid cycle, and mitochondrial biogenesis. This is the same transcriptional program that endurance exercise activates, which is why preclinical reports describe SLU-PP-332 as inducing an 'acute exercise-like' signature in skeletal muscle without the mechanical work of exercise itself.

A central research theme is substrate shifting: by upregulating fatty-acid oxidation genes, SLU-PP-332 is studied for its association with increased reliance on fat as a fuel. This places it in the same conceptual conversation as other metabolic tools that increase energy expenditure through distinct mechanisms — for example the protonophore BAM-15, which dissipates the mitochondrial proton gradient rather than reprogramming transcription.

• Agonism of estrogen-related receptors (ERRα/β/γ).
• Amplification of the PGC-1α/ERR transcriptional program.
• Upregulation of oxidative-phosphorylation and fatty-acid-oxidation genes.
• Induction of an exercise-like transcriptional signature in muscle.
• Studied for increased mitochondrial biogenesis and energy expenditure.

Metabolic and exercise-mimetic research

The defining research context for SLU-PP-332 is the exercise-mimetic concept. Preclinical rodent studies have reported that administration is associated with increased aerobic running capacity, enhanced fat oxidation, and resistance to diet-induced weight gain, with the effects attributed to the ERR-driven expansion of oxidative metabolic capacity in skeletal muscle. Researchers frame these as transcriptionally mediated changes rather than acute stimulant effects.

A notable feature reported in these models is that body-weight changes occurred without large reductions in food intake, distinguishing the mechanism from appetite-suppressing compounds. Instead, the effect is studied as an energy-expenditure phenomenon — the muscle is reprogrammed to burn more fuel — which is the conceptual link to other non-appetite metabolic agents and to the mitochondrial-derived peptide MOTS-c.

Mitochondrial biogenesis research

Because the PGC-1α/ERR axis is the principal control node for mitochondrial biogenesis, SLU-PP-332 is also studied as a probe of how pharmacologically expanding mitochondrial content affects tissue bioenergetics. In muscle and other oxidative tissues, increased ERR activity is associated with greater mitochondrial density and a more fatigue-resistant, oxidative fiber profile in preclinical models.

This mitochondrial framing is what ties SLU-PP-332 to the broader family of compounds studied for bioenergetic enhancement, including peptides encoded within the mitochondrial genome such as MOTS-c and Humanin. Each approaches mitochondrial function from a different molecular direction, and researchers study them as complementary windows into how mitochondrial capacity can be modulated.

Comparison: SLU-PP-332 vs 5-Amino-1MQ vs BAM-15

SLU-PP-332 is most usefully compared with two other non-hormonal metabolic research compounds: 5-Amino-1MQ, an inhibitor of the enzyme NNMT, and BAM-15, a mitochondrial uncoupler. All three are studied for metabolic and body-composition endpoints, but through entirely different molecular mechanisms.

The shared theme is increasing energy expenditure or remodeling metabolism without primarily suppressing appetite. Full entries for 5-Amino-1MQ and BAM-15 are available, and related compounds are catalogued in the peptide database.

Half-life and pharmacokinetic considerations

As an orally and parenterally explored small molecule, SLU-PP-332 has pharmacokinetics that differ fundamentally from injectable peptides. Early reports describe a relatively short systemic exposure that necessitated repeated administration in rodent studies, and medicinal-chemistry optimization of the ERR-agonist series has been an explicit research goal precisely because of these pharmacokinetic constraints.

Because its action is transcriptional, the relationship between plasma concentration and biological effect is indirect: the downstream gene-expression and mitochondrial changes lag behind exposure and persist after the compound is cleared. Researchers therefore treat pharmacodynamic readouts (oxidative gene expression, mitochondrial content) as distinct from the relatively short pharmacokinetic half-life.

Reconstitution and handling considerations

Unlike lyophilized peptides, SLU-PP-332 is a small molecule and is generally dissolved in an organic co-solvent (such as DMSO) for in vitro stock solutions rather than reconstituted in water. Handling emphasizes accurate weighing of a low-mass compound and protection from light and moisture.

Because the aqueous reconstitution workflow used for peptides does not directly apply, the reconstitution calculator and reconstitution guide are most relevant for the peptide compounds it is compared against rather than for SLU-PP-332 itself.

• Treat as a small molecule, not a reconstituted peptide.
• Dissolve in an appropriate organic co-solvent for stock solutions.
• Weigh accurately; low working masses amplify weighing error.
• Protect prepared stocks from light and excess warmth.

Storage considerations

Powdered SLU-PP-332 is most stable kept frozen at −20 °C, dry and away from light. Prepared stock solutions are typically refrigerated or frozen depending on the solvent, kept dark, and protected from repeated freeze–thaw cycles; aliquoting reduces how often a given stock is cycled.

Research limitations

SLU-PP-332 is an early-stage research compound, and its evidence base is limited largely to preclinical rodent and cell studies. Because the ERRs control a very broad transcriptional program across many tissues, the specificity and long-term consequences of sustained ERR agonism remain open research questions. Pharmacokinetic limitations and the absence of human data further constrain interpretation. It is described here strictly for research reference.

• Evidence is largely preclinical; human data are not established.
• ERRs regulate broad gene programs across many tissues — selectivity is an open question.
• Pharmacokinetic exposure is short and an active optimization target.
• Reported effects are model-, dose-, and design-dependent.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Billon C, Schoepke E, Avdagic A, et al. A synthetic ERR agonist alleviates metabolic syndrome. Journal of Pharmacology and Experimental Therapeutics. 2024.
2. Banerjee S, Hong S, Burris TP, et al. Pharmacological activation of estrogen-related receptors and the regulation of skeletal-muscle oxidative metabolism. Molecular Metabolism / endocrine pharmacology literature. 2024.
3. Audet-Walsh É, Giguère V. The multiple universes of estrogen-related receptor α and γ in metabolic control and related diseases. Acta Pharmacologica Sinica. 2015.